New hope for AML patients: oral drug aims to keep remission going

NCT ID NCT07458542

Ongoing Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at how well and how safely oral azacitidine (ONUREG) works as maintenance therapy for Chinese adults with acute myeloid leukemia (AML) who are in remission after initial chemotherapy. The 44 participants cannot or choose not to have a stem cell transplant. Researchers will track how long patients stay cancer-free and monitor side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oral azacitidine (ONUREG)
What this could lead to: If successful, this could confirm that oral azacitidine helps keep AML in remission longer for patients who cannot have a stem cell transplant.
What could go wrong: This is a small, real-world study in Hong Kong with only 44 participants, so results may not apply broadly. Side effects like low blood counts or infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA (AML)

Contacts and locations

Locations

The University of Hong Kong

Hong Kong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.